Senetek PLCLicensing Partner ICN Pharmaceuticals Reports Robust Sales of Kinerase(R)Within Four Months of Product Launch
Kinerase(R) Generated $6 Million in Sales to ICN
NAPA, Calif., Aug. 5 /PRNewswire/ -- Senetek PLC (Nasdaq: SNTKY - news) today announced that Kinerase®, available
as a lotion and cream, based on the Company's patented, anti-aging plant growth factor, furfuryladenine 0.1%, recently
licensed to ICN Pharmaceuticals, Inc. (NYSE: ICN - news) was highlighted in ICN's second quarter results generating sales
of $6 million since its launch in March 1999. Additionally, ICN reported that their newest product has been well received by
both clinicians and patients.
''Kinerase®, with its unique capabilities of eradicating age and sun related skin disorders, is certainly gaining recognition. We
are most enthused by both the sales volume generated by ICN's expert marketing and the potential revenues this product will
provide to Senetek's bottom-line results. The alliance Senetek consummated with ICN is demonstrating results that will benefit
our shareholders,'' stated, Frank Massino, CEO and Chairman of Senetek.
Product Overview: Kinerase® is a nature identical growth factor which partially reverses the effects of photoaging without
irritating the skin, according to studies conducted at the University of California, Irvine. These studies indicated that nearly
100% of all subjects showed improvement as measured by physicians.
ICN manufactures and markets a broad range of prescription and non-prescription pharmaceuticals and biotechnology
research products in 90 countries. The Company has operations in North and Latin America, Western, Central and Eastern
Europe, and Pacific Rim countries. Additional information is also available on ICN's corporate website at www.ichpharm.com.
Senetek PLC is a science-driven biotechnology company providing solutions to aging-related heathcare problems, in the form
of biopharmaceuticals, drug delivery systems and skincare.
The Safe Harbor Statement Under the Private Securities Litigation Reform Act Of 1995. This press release contains
forward-looking statements that involve risks and uncertainties including the risks detailed from time to time in the Company's
Securities and Exchange Commission filings.
SOURCE: Senetek PLC |
